Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 2,796 matching trials from the live ClinicalTrials.gov search.
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
72
States / cities
Sheffield, Alabama • Tucson, Arizona • Escondido, California + 60 more
Conditions
Erectile Dysfunction With Diabetes Mellitus
Interventions
Shockwave Therapy (SWT), Autologous Platelet-Rich Plasma (PRP)
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Gemcitabine, Paclitaxel, Doxorubicin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stuart, Florida + 9 more
Conditions
HIV Infections
Interventions
Tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
86
States / cities
Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more
Conditions
Hypertension, Portal
Interventions
Avenciguat (BI 685509), Placebo matching Avenciguat (BI 685509)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 3 more
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more
Active, not recruiting Not applicable Interventional

Insulin Balanced Infusion System

NCT01291719
Conditions
Hyperglycemia, Diabetes
Interventions
glucose and insulin infusions
Device
Lead sponsor
Admetsys Corporation
Industry
Eligibility
21 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2029
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

NCT05048875
Conditions
Dengue
Interventions
Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Conditions
Pain
Interventions
mepivacaine + lidocaine followed by lidocaine +lidocaine, lidocaine + lidocaine followed by mepivacaine + lidocaine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Results available

Brain Connections and Blood Pressure

NCT03736434
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Mindfulness and DASH Diet Education, Education group
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
65 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Photodamaged Skin
Interventions
Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy, Left Arm treated with vehicle serum and Intense Pulsed Light Therapy
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Completed Phase 4 Interventional Results available

B/F/TAF Switch Study for HIV-HBV Coinfection

NCT03797014
Conditions
HIV-1-infection, Hepatitis B
Interventions
B/F/TAF
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Influenza, Human+COVID-19
Interventions
Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more
Conditions
Cryotherapy Effect, Compression, Postoperative Pain Management
Interventions
Game Ready Cryotherapy with Compression Group, Control Cryotherapy Group
Device · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach

NCT01678209
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
fMRI scans, Atomoxetine arm, Methylphenidate arm
Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
ESRD
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 cream, Cal/BDP combination, Cream vehicle
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Fridley, Minnesota • Spokane, Washington
Completed Phase 3 Interventional Results available

Generalized Anxiety Disorder Adjunct Study

NCT00534599
Conditions
Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
Interventions
Placebo, quetiapine fumarate XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 50 more
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Hypoxia on Subconcussive Head Impacts

NCT04624152
Conditions
Trauma, Brain
Interventions
Soccer heading
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 26 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bloomington, Indiana
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Conditions
Dental Caries in Children, Pediatric Dental Sedation, Meperidine, Hydroxyzine, Midazolam
Interventions
Meperidine, Hydroxyzine, Midazolam
Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years to 7 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington